Replies to post #435934 on Amarin Corp Plc (AMRN)

[ralphey]

The REDUCE-IT study was designed to evaluate the effectiveness of icosapent ethyl, in reducing cardiovascular risk. Specifically, it tested whether adding icosapent ethyl to statin therapy could lower the risk of major cardiovascular events—such as heart attacks, strokes, and cardiovascular death—in patients with elevated triglyceride levels despite being on statins.

The obvious question—even a fifth grader would ask—was: would it work without the statin? Why wasn’t a statin-intolerant branch included in the study? Missing this critical piece has cost people billions of dollars. If that’s not gross incompetence, I don’t know what is.

What Ralphey Says

Dont run a study well and your stock will go to hell

[north40000]

Wrong idea. Work with FDA. Lovaza has no CVD benefit according to FDA data sheet. Ask FDA to enforce that data in the interest of M and W public health.See FDA  Compliance Policy Guide 120.100. Send a letter to nation's doctors with notice not to write off-label scrips for Lovaza with CVD indications.